Should ceftriaxone-resistant Enterobacterales be tested for ESBLs? A PRO/CON debate

Autores organización

• 

  Maria Virginia Villegas Botero

  Autor

• 

  Jinnethe Cristina Reyes Manrique

  Autor

Autores

• Esparza, G

Grupos de investigación

• Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria RAEH

  

  Investigador

  Maria Virginia Villegas Botero

• Unidad de Genética y Resistencia Antimicrobiana UGRA

Resumen

ESBLs are a group of plasmid-mediated, diverse, complex and rapidly evolving enzymes that pose a therapeutic challenge today in hospital- and community-acquired infections. Thirty-six years after the first report, diagnostic and therapeutic approaches for ESBLs are still the subject of controversy. Detection of these enzymes is recommended for epidemiological purposes and facilitates targeted therapy, necessary for antimicrobial stewardship. On the other hand, ESBLs are not confined to specific species, phenotypic detection methods have pitfalls, and concerns exist about the accuracy of antimicrobial susceptibility testing systems to rely on MIC values for cephalosporins and beta-lactam combination agents. In this issue, we present a PRO/CON debate on ESBL testing for ceftriaxone-non-susceptible Enterobacterales.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.

Keywords

• carbapenem; carbapenemase; ceftriaxone; extended spectrum beta lactamase; antibiotic sensitivity; Article; cephalosporin resistance; extended spectrum beta lactamase producing Enterobacteriaceae; human; inoculation; Klebsiella pneumoniae; minimum inhibitory concentration; nonhuman; phenotype; protein expression